Literature DB >> 29270700

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.

Gabriele Romano1, Lawrence N Kwong2.   

Abstract

Cancer immunotherapy has shown impressive clinical results in the last decade, improving both solid and hematologic cancer patients' overall survival. Nevertheless, most of the molecular aspects underlying the response to this approach are still under investigation. miRNAs in particular have been described as regulators of a plethora of different immunologic processes and thus have the potential to be key in the future developments of immunotherapy. In this review, we summarize and discuss the emerging role of miRNAs in the diagnosis and therapeutics of the four principal cancer immunotherapy approaches: immune checkpoint blockade, adoptive cell therapy, cancer vaccines, and cytokine therapy. In particular, this review is focused on potential roles for miRNAs to be adjuvants in soluble factor- and cell-based therapies, with the aim of helping to increase specificity and decrease toxicity, and on the potential for rationally identified miRNA-based diagnostic approaches to aid in precision clinical immunooncology.

Entities:  

Keywords:  Cancer diagnostics; Cancer immunotherapy; Immune-based therapies; miRNAs

Mesh:

Substances:

Year:  2018        PMID: 29270700     DOI: 10.1007/s10555-017-9716-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  11 in total

1.  miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Mariarosaria Incoronato
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

2.  miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.

Authors:  Jihua Han; Meiyin Zhang; Chunlei Nie; Jinliang Jia; Fengyue Wang; Jiawei Yu; Wen Bi; Bo Liu; Ruinan Sheng; Guoqing He; Lingyu Kong; Lingling Zheng; Rui Pang; Zhaoming Ding; Lili Chen; Qiang Guan; Shangha Pan; Xianzhi Meng; Jin Xu; Lianxin Liu; Jiewu Zhang
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

Review 3.  Current Perspectives in Cancer Immunotherapy.

Authors:  Theodoulakis Christofi; Stavroula Baritaki; Luca Falzone; Massimo Libra; Apostolos Zaravinos
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

4.  Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.

Authors:  Dong-Yan Zhao; Xi-Zhen Sun; Shu-Kun Yao
Journal:  World J Gastrointest Oncol       Date:  2021-01-15

5.  Serum MiR-4687-3p Has Potential for Diagnosis and Carcinogenesis in Non-small Cell Lung Cancer.

Authors:  Man Liu; Qiufang Si; Songyun Ouyang; Zhigang Zhou; Meng Wang; Chunling Zhao; Ting Yang; Yulin Wang; Xue Zhang; Wenbo Xie; Liping Dai; Jitian Li
Journal:  Front Genet       Date:  2020-11-23       Impact factor: 4.599

Review 6.  The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy.

Authors:  Yuhe Lei; Lei Chen; Junshan Liu; Yinqin Zhong; Lijuan Deng
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 7.  MicroRNAs: immune modulators in cancer immunotherapy.

Authors:  Yun Xing; Zhiqiang Wang; Zhou Lu; Jie Xia; Zhangjuan Xie; Mengxia Jiao; Ronghua Liu; Yiwei Chu
Journal:  Immunother Adv       Date:  2021-05-13

8.  The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence.

Authors:  Shariq S Khwaja; Chunyu Cai; Shahed N Badiyan; Xiaowei Wang; Jiayi Huang
Journal:  Oncotarget       Date:  2018-06-26

Review 9.  Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs.

Authors:  Patrizia Leone; Alessio Buonavoglia; Rossella Fasano; Antonio Giovanni Solimando; Valli De Re; Sebastiano Cicco; Angelo Vacca; Vito Racanelli
Journal:  J Clin Med       Date:  2019-11-20       Impact factor: 4.241

Review 10.  The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies.

Authors:  Zhengjia Zhang; Qingcai Huang; Liuchunyang Yu; Dongjie Zhu; Yang Li; Zeyu Xue; Zhenglai Hua; Xinyi Luo; Zhiqian Song; Cheng Lu; Ting Zhao; Yuanyan Liu
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.